Aumolertinib Versus Osimertinib as First‐Line Treatment for <scp>EGFR</scp> ‐Mutant Non‐Small Cell Lung Cancer: A Retrospective Real‐World Multicenter Study

Jinxia Wang, Ping Qi, Jinhua Li, Na Wang, Caihong Fu, Lixin Liu, Shuping Li, Xiao Li, Xiaoming Hou, Hui Qiao

Open source

DOI: 10.1002/ijc.70617
Published: 2026-08-04
Container: International Journal of Cancer
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/ijc.70617,
  title = {Aumolertinib Versus Osimertinib as First‐Line Treatment for
                    <scp>EGFR</scp>
                    ‐Mutant Non‐Small Cell Lung Cancer: A Retrospective Real‐World Multicenter Study},
  author = {Jinxia Wang and Ping Qi and Jinhua Li and Na Wang and Caihong Fu and Lixin Liu and Shuping Li and Xiao Li and Xiaoming Hou and Hui Qiao},
  year = {2026},
  journal = {International Journal of Cancer},
  doi = {10.1002/ijc.70617},
  url = {https://doi.org/10.1002/ijc.70617}
}

RIS

TY  - JOUR
TI  - Aumolertinib Versus Osimertinib as First‐Line Treatment for
                    <scp>EGFR</scp>
                    ‐Mutant Non‐Small Cell Lung Cancer: A Retrospective Real‐World Multicenter Study
AU  - Jinxia Wang
AU  - Ping Qi
AU  - Jinhua Li
AU  - Na Wang
AU  - Caihong Fu
AU  - Lixin Liu
AU  - Shuping Li
AU  - Xiao Li
AU  - Xiaoming Hou
AU  - Hui Qiao
PY  - 2026
JO  - International Journal of Cancer
DO  - 10.1002/ijc.70617
UR  - https://doi.org/10.1002/ijc.70617
ER  -

APA

Wang, J., Qi, P., Li, J., Wang, N., Fu, C., Liu, L., Li, S., Li, X., Hou, X., & Qiao, H. (2026). Aumolertinib Versus Osimertinib as First‐Line Treatment for <scp>EGFR</scp> ‐Mutant Non‐Small Cell Lung Cancer: A Retrospective Real‐World Multicenter Study. International Journal of Cancer. https://doi.org/10.1002/ijc.70617

Source records

crossref · retrieved 2026-09-27T04:25:19.752Z